2016 Annual Meeting | Interventional Treatment of Migraine and Other Headache Disorders
| 06:30 AM - 06:40 AM | Introduction Morris Levin, MD, FAAN | |
| 06:40 AM - 07:00 AM | Nerve Blocks and Trigger Point Injections: Pharmacology and Technique Morris Levin, MD, FAAN | |
| 07:00 AM - 07:20 AM | Evidence for Nerve Blocks and Trigger Point Injections in Headache Thomas N. Ward, MD, FAAN | |
| 07:20 AM - 07:50 AM | Neurostimulation in Primary Headache Disorders – Options and Evidence Morris Levin, MD, FAAN | |
| 07:50 AM - 08:15 AM | Inpatient Treatment of Headache – Options and Outcomes Thomas N. Ward, MD, FAAN | |
| 08:15 AM - 08:30 AM | Questions and Answers | 
| Morris Levin, MD, FAAN | Dr. Levin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus, Upsher Smith, Biohaven, Revance, Percept, Theranica, Allergan, Alder, Currax. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Attorney . Dr. Levin has received stock or an ownership interest from Percept. Dr. Levin has received publishing royalties from a publication relating to health care. | 
| Thomas N. Ward, MD, FAAN | No disclosure on file |